From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

MGC Pharmaceuticals – do the maths dummies, I'm 99.2% ahead on this bear call and it is going to go from £15m now to zero

By Tom Winnifrith | Wednesday 31 January 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


On November 1 2022, I published a red flags dossier on Turner Pope spoof MGC Pharmaceuticals (MXC) with the shares at 2.25p giving market cap of £70 million. Wind forward 15 months and after a 1000 for 1 consolidation the shares are 18p meaning that those who mocked my advice have lost 99.2% of their hard earned. But so many gazillion pieces of worthless confetti have been issued that the market cap is still £15 million and today’s quarterlies suggest that is way too high as yet another cash crisis looms.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

VANL

Van Elle Holdings – a Buy?

Thursday »

CCT

Character Group – a Buy?

 

ING

Ingenta – now a Buy again?

 

Clown

Which PR genius wrote this?

Time left: 08:17:00